Standout Papers

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate... 2008 2026 2014 2020 1.2k
  1. Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate (2008)
    Gail D. Lewis Phillips, Guangmin Li et al. Cancer Research
  2. Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer (2014)
    John M. Lambert, Ravi Chari Journal of Medicinal Chemistry
  3. Antibody–drug conjugates come of age in oncology (2023)
    Charles Dumontet, Janice M. Reichert et al. Nature Reviews Drug Discovery

Immediate Impact

38 by Nobel laureates 17 from Science/Nature 81 standout
Sub-graph 1 of 22

Citing Papers

Principles and therapeutic applications of adaptive immunity
2024 Standout
Biomimetic Nanoerythrosome‐Coated Aptamer–DNA Tetrahedron/Maytansine Conjugates: pH‐Responsive and Targeted Cytotoxicity for HER2‐Positive Breast Cancer
2022 Standout

Works of John M. Lambert being referenced

Antibody–drug conjugates come of age in oncology
2023 Standout
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
2008 Standout

Author Peers

Author Last Decade Papers Cites
John M. Lambert 3803 1755 3924 3336 127 8.0k
Janice M. Reichert 5012 2303 2313 5389 92 9.4k
Victor S. Goldmacher 2081 1553 2410 2734 90 6.5k
David Colcher 6580 1840 3140 3884 206 9.8k
Zenon Steplewski 5316 3346 3110 6135 172 10.9k
Donald J. Buchsbaum 1862 1349 3360 4683 274 9.0k
Silvana Canevari 1862 2224 3171 4311 225 8.6k
Dorothee Herlyn 3818 3214 3254 3909 154 8.3k
K E Hellström 3055 3112 2031 3017 106 7.1k
Philip E. Thorpe 1385 3426 2529 5720 134 10.4k
Alan F. Wahl 1937 1074 3218 3074 64 6.8k

All Works

Loading papers...

Rankless by CCL
2026